BRCA1, a 'complex' protein involved in the maintenance of genomic stability

FEBS Journal

Volumn 282, Issue 4, 2015, Pages 630-646

  Savage, Kienan I ^a   Harkin, D Paul ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

BRCA1; breast cancer; DNA damage response; DNA repair; genomic instability; hereditary breast cancer

Indexed keywords

BRCA1 PROTEIN; ESTROGEN RECEPTOR ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; TRANSCRIPTION FACTOR RELA; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE ARREST; CHEMOPROPHYLAXIS; COMPLEX FORMATION; DNA REPAIR; DRUG SENSITIVITY; GENOMIC INSTABILITY; HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; RNA SPLICING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; ANIMAL; BREAST TUMOR; DNA DAMAGE; FEMALE; GENETICS; METABOLISM; PHYSIOLOGY;

ANIMALS; BRCA1 PROTEIN; BREAST NEOPLASMS; DNA DAMAGE; DNA REPAIR; FEMALE; GENOMIC INSTABILITY; HUMANS;

EID: 84923188432     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13150     Document Type: Review

References (109)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al,. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66-71.
2. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, &, Micklem G, (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789-792.
3. Foulkes WD, (2008) Inherited susceptibility to common cancers. N Engl J Med 359, 2143-2153.
4. Welcsh PL, &, King MC, (2001) BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 10, 705-713.
5. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, et al,. (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92, 564-569.
6. Deng C-X, &, Scott F, (2000) Role of the tumour suppressor gene BRCA1 in genetic stability and mammary gland tumour formation. Oncogene 19, 1059-1064.
7. Savage KI, &, Harkin DP, (2009) BRCA1 and BRCA2: role in the DNA damage response, cancer formation and treatment. In The DNA Damage Response: Implications on Cancer Formation and Treatment (, Shiloh Y, &, Khanna KK, eds), pp. 415-443. Springer, Netherlands.
8. Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y, Ogata H, &, Ohta T, (2001) The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 276, 14537-14540.
9. Wu W, Koike A, Takeshita T, &, Ohta T, (2008) The ubiquitin E3 ligase activity of BRCA1 and its biological functions. Cell Div 3, 1.
10. Zhu Q, Pao GM, Huynh AM, Suh H, Tonnu N, Nederlof PM, Gage FH, &, Verma IM, (2011) BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature 477, 179-184.
11. Shakya R, Reid LJ, Reczek CR, Cole F, Egli D, Lin CS, Derooij DG, Hirsch S, Ravi K, Hicks JB, et al,. (2011) BRCA1 tumor suppression depends on BRCT phosphoprotein binding, But not its E3 ligase activity. Science 334, 525-528.
12. Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S, Klijn C, van der Heijden I, van der Gulden H, Wientjens E, et al,. (2011) BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell 20, 797-809.
13. Chapman MS, &, Verma IM, (1996) Transcriptional activation by BRCA1. Nature 382, 678-679.
14. Monteiro AN, August A, &, Hanafusa H, (1996) Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA 93, 13595-13599.
15. Yu X, Chini CCS, He M, Mer G, &, Chen J, (2003) The BRCT domain is a phospho-protein binding domain. Science 302, 639-642.
16. Manke IA, Lowery DM, Nguyen A, &, Yaffe MB, (2003) BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science 302, 636-639.
17. Thakur S, Zhang HB, Peng Y, Le H, Carroll B, Ward T, Yao J, Farid LM, Couch FJ, Wilson RB, et al,. (1997) Localisation of BRCA1 and a splice variant identifies the nuclear localisation signal. Mol Cell Biol 17, 444-452.
18. Rodriguez JA, &, Henderson BR, (2000) Identification of a functional nuclear export sequence in BRCA1. J Biol Chem 275, 38589-38596.
19. Venkitaraman AR, (2014) Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science 343, 1470-1475.
20. Dunker AK, Cortese MS, Romero P, Iakoucheva LM, &, Uversky VN, (2005) Flexible nets, The roles of intrinsic disorder in protein interaction networks. FEBS J 272, 5129-5148.
21. Khanna KK, &, Jackson SP, (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27, 247-254.
22. Liu C, Srihari S, Cao KA, Chenevix-Trench G, Simpson PT, Ragan MA, &, Khanna KK, (2014) A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy. Nucleic Acids Res 42, 6106-6127.
23. Wei L, Lan L, Hong Z, Yasui A, Ishioka C, &, Chiba N, (2008) Rapid recruitment of BRCA1 to DNA double-strand breaks is dependent on its association with Ku80. Mol Cell Biol 28, 7380-7393.
24. Zhong Q, Boyer TG, Chen PL, &, Lee WH, (2002) Deficient nonhomologous end-joining activity in cell-free extracts from BRCA1-null fibroblasts. Cancer Res 62, 3966-3970.
25. Zhong Q, Chen CF, Chen PL, &, Lee WH, (2002) BRCA1 facilitates microhomology-mediated end joining of DNA double strand breaks. J Biol Chem 277, 28641-28647.
26. Moynahan ME, Chiu JW, Koller BH, &, Jasin M, (1999) BRCA1 controls homology-directed DNA repair. Mol Cell 4, 511-518.
27. Snouwaert JN, Gowen LC, Latour AM, Mohn AR, Xiao A, DiBiase L, &, Koller BH, (1999) BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene. Oncogene 18, 7900-7907.
28. Greenberg RA, Sobhian B, Pathania S, Cantor SB, Nakatani Y, &, Livingston DM, (2006) Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev 20, 34-46.
29. Huertas P, &, Jackson SP, (2009) Human CtIP mediates cell cycle control of DNA end resection and double strand break repair. J Biol Chem 284, 9558-9565.
30. Yu X, &, Chen J, (2004) DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-Terminal domains. Mol Cell Biol 24, 9478-9486.
31. Reczek CR, Szabolcs M, Stark JM, Ludwig T, &, Baer R, (2013) The interaction between CtIP and BRCA1 is not essential for resection-mediated DNA repair or tumor suppression. J Cell Biol 201, 693-707.
32. Polato F, Callen E, Wong N, Faryabi R, Bunting S, Chen HT, Kozak M, Kruhlak MJ, Reczek CR, Lee WH, et al,. (2014) CtIP-mediated resection is essential for viability and can operate independently of BRCA1. J Exp Med 211, 1027-1036.
33. Cruz-Garcia A, Lopez-Saavedra A, &, Huertas P, (2014) BRCA1 accelerates CtIP-mediated DNA-end resection. Cell Rep 9, 451-459.
34. Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao L, et al,. (2010) 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141, 243-254.
35. Zimmermann M, &, de Lange T, (2014) 53BP1: pro choice in DNA repair. Trends Cell Biol 24, 108-117.
36. Escribano-Diaz C, Orthwein A, Fradet-Turcotte A, Xing M, Young JT, Tkac J, Cook MA, Rosebrock AP, Munro M, Canny MD, et al,. (2013) A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. Mol Cell 49, 872-883.
37. Chapman JR, Sossick AJ, Boulton SJ, &, Jackson SP, (2012) BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies temporal control of DNA repair. J Cell Sci 125, 3529-3534.
38. Kakarougkas A, Ismail A, Katsuki Y, Freire R, Shibata A, &, Jeggo PA, (2013) Co-operation of BRCA1 and POH1 relieves the barriers posed by 53BP1 and RAP80 to resection. Nucleic Acids Res 41, 10298-10311.
39. Butler LR, Densham RM, Jia J, Garvin AJ, Stone HR, Shah V, Weekes D, Festy F, Beesley J, &, Morris JR, (2012) The proteasomal de-ubiquitinating enzyme POH1 promotes the double-strand DNA break response. EMBO J 31, 3918-3934.
40. Hu Y, Scully R, Sobhian B, Xie A, Shestakova E, &, Livingston DM, (2011) RAP80-directed tuning of BRCA1 homologous recombination function at ionizing radiation-induced nuclear foci. Genes Dev 25, 685-700.
41. Coleman KA, &, Greenberg RA, (2011) The BRCA1-RAP80 complex regulates DNA repair mechanism utilization by restricting end resection. J Biol Chem 286, 13669-13680.
42. Xie J, Peng M, Guillemette S, Quan S, Maniatis S, Wu Y, Venkatesh A, Shaffer SA, Brosh RM Jr, &, Cantor SB, (2012) FANCJ/BACH1 acetylation at lysine 1249 regulates the DNA damage response. PLoS Genet 8, e1002786.
43. Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B, &, Yu X, (2009) PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol 19, 524-529.
44. Sy SM, Huen MS, &, Chen J, (2009) PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci USA 106, 7155-7160.
45. Stucki M, Clapperton JA, Mohammad D, Yaffe MB, Smerdon SJ, &, Jackson SP, (2005) MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell 123, 1213-1226.
46. Doil C, Mailand N, Bekker-Jensen S, Menard P, Larsen DH, Pepperkok R, Ellenberg J, Panier S, Durocher D, Bartek J, et al,. (2009) RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell 136, 435-446.
47. Stewart GS, Panier S, Townsend K, Al-Hakim AK, Kolas NK, Miller ES, Nakada S, Ylanko J, Olivarius S, Mendez M, et al,. (2009) The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage. Cell 136, 420-434.
48. Bekker-Jensen S, Lukas C, Kitagawa R, Melander F, Kastan MB, Bartek J, &, Lukas J, (2006) Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. J Cell Biol 173, 195-206.
49. Mailand N, Bekker-Jensen S, Faustrup H, Melander F, Bartek J, Lukas C, &, Lukas J, (2007) RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 131, 887-900.
50. Baer R, (2013) Luring BRCA1 to the scene of the crime. Cancer Cell 23, 565-567.
51. Li M, &, Yu X, (2013) Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. Cancer Cell 23, 693-704.
52. Taniguchi T, Garcia-Higuera I, Andreassen PR, Gregory RC, Grompe M, &, D'Andrea AD, (2002) S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 100, 2414-2420.
53. Kim H, &, D'Andrea AD, (2012) Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev 26, 1393-1408.
54. Bunting SF, Callen E, Kozak ML, Kim JM, Wong N, Lopez-Contreras AJ, Ludwig T, Baer R, Faryabi RB, Malhowski A, et al,. (2012) BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. Mol Cell 46, 125-135.
55. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, &, Qin J, (2000) BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14, 927-939.
56. Wood RD, (1997) Nucleotide excision repair in mammalian cells. J Biol Chem 272, 23465-23468.
57. Le Page F, Randrianarison V, Marot D, Cabannes J, Perricaudet M, Feunteun J, &, Sarasin A, (2000) BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells. Cancer Res 60, 5548-5552.
58. Kleiman FE, Wu-Baer F, Fonseca D, Kaneko S, Baer R, &, Manley JL, (2005) BRCA1/BARD1 inhibition of mRNA 3 processing involves targeted degradation of RNA polymerase II. Genes Dev 19, 1227-1237.
59. Starita LM, Horwitz AA, Keogh M-C, Ishioka C, Parvin JD, &, Chiba N, (2005) BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II. J Biol Chem 280, 24498-24505.
60. Hartman A-R, &, Ford JM, (2002) BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat Genet 32, 180-184.
61. Humphrey JS, Salim A, Erdos MR, Collins FS, Brody LC, &, Klausner RD, (1997) Human BRCA1 inhibits growth in yeast: potential use in diagnostic testing. PNAS 94, 5820-5825.
62. Fabbro M, Savage K, Hobson K, Deans AJ, Powell SN, McArthur GA, &, Khanna KK, (2004) BRCA1-BARD1 complexes are required for p53Ser-15 phosphorylation and a G1/S arrest following ionizing radiation-induced DNA damage. J Biol Chem 279, 31251-31258.
63. MacLachlan TK, Takimoto R, &, El-Deiry WS, (2002) BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol Cell Biol 22, 4280-4292.
64. Andrews HN, Mullan PB, McWilliams S, Sebelova S, Quinn JE, Gilmore PM, McCabe N, Pace A, Koller B, Johnston PG, et al,. (2002) BRCA1 regulates the interferon gamma -mediated apoptotic response. J Biol Chem 277, 26225-26232.
65. Harte MT, Gorski JJ, Savage KI, Purcell JW, Barros EM, Burn PM, McFarlane C, Mullan PB, Kennedy RD, Perkins ND, et al,. (2014) NF-kappaB is a critical mediator of BRCA1-induced chemoresistance. Oncogene 33, 713-723.
66. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Strom A, Treuter E, Warner M, et al,. (2007) Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87, 905-931.
67. Fan S, Ma YX, Wang C, Yuan R-Q, Meng Q, Wang J-A, Erdos M, Goldberg ID, Webb P, Kushner PJ, et al,. (2001) Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 20, 77-87.
68. Zheng L, Annab LA, Afshari CA, Lee WH, &, Boyer TG, (2001) BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci USA 98, 9587-9592.
69. Kawai H, Li H, Chun P, Avraham S, &, Avraham HK, (2002) Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene 21, 7730-7739.
70. Aiyar SE, Sun J-L, Blair AL, Moskaluk CA, Lu Y-Z, Ye Q-N, Yamaguchi Y, Mukherjee A, Ren D-M, Handa H, et al,. (2004) Attenuation of estrogen receptor {alpha}-mediated transcription through estrogen-stimulated recruitment of a negative elongation factor. Genes Dev 18, 2134-2146.
71. Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE, James CR, Farragher SM, Mulligan JM, Scott AN, et al,. (2007) Molecular basis for Estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 99, 1683-1694.
72. Chen G-C, Guan L-S, Yu J-H, Li G-C, Kim H-RC, &, Wang Z-Y, (2001) Rb-associated protein 46 (RbAp46) inhibits transcriptional transactivation mediated by BRCA1. Biochem Biophys Res Commun 284, 507-514.
73. Yarden RI, &, Brody LC, (1999) BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci USA 96, 4983-4988.
74. Harte MT, O'Brien GJ, Ryan NM, Gorski JJ, Savage KI, Crawford NT, Mullan PB, &, Harkin DP, (2010) BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription. Cancer Res 70, 2538-2547.
75. Kadam S, McAlpine GS, Phelan ML, Kingston RE, Jones KA, &, Emerson BM, (2000) Functional selectivity of recombinant mammalian SWI/SNF subunits. Genes Dev 14, 2441-2451.
76. Fan W, Jin S, Tong T, Zhao H, Fan F, Antinore MJ, Rajasekaran B, Wu M, &, Zhan Q, (2002) BRCA1 regulates GADD45 through its interactions with the OCT-1 and CAAT motifs. J Biol Chem 277, 8061-8067.
77. Harkin DP, Bean JM, Miklos D, Song Y-H, Truong VB, Englert C, Christians FC, Ellisen LW, Maheswaran S, Oliner JD, et al,. (1999) Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 97, 575-586.
78. Saha T, Rih JK, Roy R, Ballal R, &, Rosen EM, (2010) Transcriptional regulation of the base excision repair pathway by BRCA1. J Biol Chem 285, 19092-19105.
79. Li S, Chen P-L, Subramanian T, Chinnadurai G, Tomlinson G, Osborne CK, Sharp ZD, &, Lee W-H, (1999) Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage. J Biol Chem 274, 11334-11338.
80. Yu X, Wu LC, Bowcock AM, Aronheim A, &, Baer R, (1998) The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathways of transcriptional repression. J Biol Chem 273, 25388-25392.
81. Zheng L, Pan H, Li S, Flesken-Nikitin A, Chen PL, Boyer TG, &, Lee WH, (2000) Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. Mol Cell 6, 757-768.
82. Furuta S, Wang JM, Wei S, Jeng YM, Jiang X, Gu B, Chen PL, Lee EY, &, Lee WH, (2006) Removal of BRCA1/CtIP/ZBRK1 repressor complex on ANG1 promoter leads to accelerated mammary tumor growth contributed by prominent vasculature. Cancer Cell 10, 13-24.
83. Kennedy RD, Gorski JJ, Quinn JE, Stewart GE, James CR, Moore S, Mulligan K, Emberley ED, Lioe TF, Morrison PJ, et al,. (2005) BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. Cancer Res 65, 10265-10272.
84. Li H, Lee T-H, &, Avraham H, (2002) A novel tricomplex of BRCA1, Nmi, and c-Myc Inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J Biol Chem 277, 20965-20973.
85. Gorski JJ, Savage KI, Mulligan JM, McDade SS, Blayney JK, Ge Z, &, Harkin DP, (2011) Profiling of the BRCA1 transcriptome through microarray and ChIP-chip analysis. Nucleic Acids Res 39, 9536-9548.
86. Chiba N, &, Parvin JD, (2001) Redistribution of BRCA1 among four different protein complexes following replication blockage. J Biol Chem 276, 38549-38554.
87. Savage KI, Gorski JJ, Barros EM, Irwin GW, Manti L, Powell AJ, Pellagatti A, Lukashchuk N, McCance DJ, McCluggage WG, et al,. (2014) Identification of a BRCA1-mRNA splicing complex required for efficient DNA repair and maintenance of genomic stability. Mol Cell 54, 445-459.
88. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, et al,. (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346, 1609-1615.
89. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, et al,. (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346, 1616-1622.
90. Kotsopoulos J, Lubinski J, Lynch HT, Kim-Sing C, Neuhausen S, Demsky R, Foulkes WD, Ghadirian P, Tung N, Ainsworth P, et al,. (2012) Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 21, 1089-1096.
91. Jernstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, Daly M, Olopade OI, Foulkes WD, Warner E, et al,. (1999) Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 354, 1846-1850.
92. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, et al,. (2012) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 21, 134-147.
93. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, &, Arun BK, (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26, 4282-4288.
94. Savage KI, Matchett KB, Barros EM, Cooper KM, Irwin GW, Gorski JJ, Orr KS, Vohhodina J, Kavanagh JN, Madden AF, et al,. (2014) BRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instability. Cancer Res 74, 2773-2784.
95. Gorrini C, Baniasadi PS, Harris IS, Silvester J, Inoue S, Snow B, Joshi PA, Wakeham A, Molyneux SD, Martin B, et al,. (2013) BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med 210, 1529-1544.
96. Gorrini C, Gang BP, Bassi C, Wakeham A, Baniasadi SP, Hao Z, Li WY, Cescon DW, Li YT, Molyneux S, et al,. (2014) Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway. Proc Natl Acad Sci USA 111, 4472-4477.
97. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, &, Harkin DP, (2003) BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 63, 6221-6228.
98. Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ, et al,. (2004) BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13, 2443-2449.
99. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al,. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921.
100. Lee JM, Ledermann JA, &, Kohn EC, (2014) PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol 25, 32-40.
101. Mulligan JM, Hill LA, Deharo S, Irwin G, Boyle D, Keating KE, Raji OY, McDyer FA, O'Brien E, Bylesjo M, et al,. (2014) Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer. J Natl Cancer Inst 106, djt335.
102. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, et al,. (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) breast cancer prevention trial. JAMA 286, 2251-2256.
103. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, et al,. (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22, 2328-2335.
104. Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, Frost D, Easton DF, Ellis S, Friedlander ML, et al,. (2013) Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol 31, 3091-3099.
105. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P, et al,. (2005) Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 23, 7491-7496.
106. Del Mastro L, Levaggi A, Giraudi S, &, Pronzato P, (2011) Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives. Cancer Treat Rev 37, 208-211.
107. Rossi E, Morabito A, De Maio E, Di Rella F, Esposito G, Gravina A, Labonia V, Landi G, Nuzzo F, Pacilio C, et al,. (2008) Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer. J Clin Oncol 26, 264-270.
108. Cao L, Xu X, Bunting SF, Liu J, Wang RH, Cao LL, Wu JJ, Peng TN, Chen J, Nussenzweig A, et al,. (2009) A selective requirement for 53BP1 in the biological response to genomic instability induced by BRCA1 deficiency. Mol Cell 35, 534-541.
109. Iwabuchi K, Li B, Massa HF, Trask BJ, Date T, &, Fields S, (1998) Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2. J Biol Chem 273, 26061-26068.